[Malignant melanoma: conceptual and therapeutic innovations based on translational research].
The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are presented. The concept of the duality between fast-growing (high malignancy) and slow-growing (reduced malignancy) melanoma is stressed. A new international multicentric approach using adjuvant therapy for stage III melanomas involves the clinical oncology department of the CHU of Liège. It concerns a targeted immunotherapy directed to the Mage A3 protein.
Piérard
G E
GE
Service de Dermatopathologie, CHU du Sart Tilman, Liège, Belgique. gerald.pierard@ulg.ac.be
Quatresooz
P
P
Rorive
A
A
Piérard-Franchimont
C
C
D000951:Antigens, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007167:Immunotherapy; D007275:Injections, Intravenous; D016898:Interferon-alpha / Q000008:administration & dosage; D008545:Melanoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D016898:Interferon-alpha; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins